978 related articles for article (PubMed ID: 9808682)
21. Metabolism of bradykinin by peptidases in the lung.
Dragović T; Igić R; Erdös EG; Rabito SF
Am Rev Respir Dis; 1993 Jun; 147(6 Pt 1):1491-6. PubMed ID: 8389109
[TBL] [Abstract][Full Text] [Related]
22. Determinants of in vivo activity of neutral endopeptidase 3.4.24.11 and angiotensin converting enzyme inhibitors.
Seymour AA; Asaad MM; Abboa-Offei BE; Smith PL; Rogers WL; Dorso CR
J Pharmacol Exp Ther; 1996 Feb; 276(2):708-13. PubMed ID: 8632340
[TBL] [Abstract][Full Text] [Related]
23. Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy.
Tschöpe C; Seidl U; Reinecke A; Riester U; Graf K; Schultheiss HP; Hilgenfeldt U; Unger T
Int Immunopharmacol; 2003 Mar; 3(3):335-44. PubMed ID: 12639811
[TBL] [Abstract][Full Text] [Related]
24. Potentiation of bradykinin effect by angiotensin-converting enzyme inhibition does not correlate with angiotensin-converting enzyme activity in the rat mesenteric arteries.
Sivieri DO; Bispo-da-Silva LB; Oliveira EB; Resende AC; Salgado MC
Hypertension; 2007 Jul; 50(1):110-5. PubMed ID: 17470724
[TBL] [Abstract][Full Text] [Related]
25. Effects of alatriopril, a mixed inhibitor of atriopeptidase and angiotensin I-converting enzyme, on cardiac hypertrophy and hormonal responses in rats with myocardial infarction. Comparison with captopril.
Bralet J; Marie C; Mossiat C; Lecomte JM; Gros C; Schwartz JC
J Pharmacol Exp Ther; 1994 Jul; 270(1):8-14. PubMed ID: 8035346
[TBL] [Abstract][Full Text] [Related]
26. Optimal recognition of neutral endopeptidase and angiotensin-converting enzyme active sites by mercaptoacyldipeptides as a means to design potent dual inhibitors.
Coric P; Turcaud S; Meudal H; Roques BP; Fournie-Zaluski MC
J Med Chem; 1996 Mar; 39(6):1210-9. PubMed ID: 8632427
[TBL] [Abstract][Full Text] [Related]
27. Bradykinin metabolism in rat hearts with left-ventricular hypertrophy following myocardial infarction.
Dumoulin MJ; Adam A; Rouleau JL; Gosselin H; Lamontagne D
Can J Physiol Pharmacol; 2003 Jul; 81(7):740-6. PubMed ID: 12897822
[TBL] [Abstract][Full Text] [Related]
28. Angiotensin I-converting enzyme-dependent and neutral endopeptidase-dependent generation and degradation of angiotensin II contrarily modulate noradrenaline release: implications for vasopeptidase-inhibitor therapy?
Raasch W; Dominiak P; Dendorfer A
J Hypertens; 2005 Aug; 23(8):1597-604. PubMed ID: 16003188
[TBL] [Abstract][Full Text] [Related]
29. Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts.
Blais C; Fortin D; Rouleau JL; Molinaro G; Adam A
J Pharmacol Exp Ther; 2000 Nov; 295(2):621-6. PubMed ID: 11046097
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of neutral endopeptidase by thiorphan does not modify coronary vascular responses to angiotensin I, angiotensin II and bradykinin in the isolated guinea pig heart.
Kozlovski VI; Lomnicka M; Jakubowski A; Chlopicki S
Pharmacol Rep; 2007; 59(4):421-7. PubMed ID: 17901571
[TBL] [Abstract][Full Text] [Related]
31. Effect of chronic treatment with the vasopeptidase inhibitor AVE 7688 and ramipril on endothelial function in atherogenic diet rabbits.
Weckler N; Leitzbach D; Kalinowski L; Malinski T; Busch AE; Linz W
J Renin Angiotensin Aldosterone Syst; 2003 Sep; 4(3):191-6. PubMed ID: 14608526
[TBL] [Abstract][Full Text] [Related]
32. Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action.
Fournie-Zaluski MC; Coric P; Thery V; Gonzalez W; Meudal H; Turcaud S; Michel JB; Roques BP
J Med Chem; 1996 Jun; 39(13):2594-608. PubMed ID: 8691458
[TBL] [Abstract][Full Text] [Related]
33. Effect of angiotensin II and bradykinin inhibition in rat reduced-size liver transplantation.
Padrissa-Altés S; Franco-Gou R; Boillot O; Serafín A; Rimola A; Arroyo V; Rodés J; Peralta C; Roselló-Catafau J
Liver Transpl; 2009 Mar; 15(3):313-20. PubMed ID: 19242996
[TBL] [Abstract][Full Text] [Related]
34. Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: insights from selective inhibitors.
Georgiadis D; Beau F; Czarny B; Cotton J; Yiotakis A; Dive V
Circ Res; 2003 Jul; 93(2):148-54. PubMed ID: 12805239
[TBL] [Abstract][Full Text] [Related]
35. Combined inhibition of neutral endopeptidase and angiotensin converting enzyme in cardiomyopathic hamsters with compensated heart failure.
Trippodo NC; Fox M; Natarajan V; Panchal BC; Dorso CR; Asaad MM
J Pharmacol Exp Ther; 1993 Oct; 267(1):108-16. PubMed ID: 8229737
[TBL] [Abstract][Full Text] [Related]
36. Reversal of cardiac hypertrophy and fibrosis by S21402, a dual inhibitor of neutral endopeptidase and angiotensin converting enzyme in SHRs.
Farina NK; Johnston CI; Burrell LM
J Hypertens; 2000 Jun; 18(6):749-55. PubMed ID: 10872560
[TBL] [Abstract][Full Text] [Related]
37. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors.
Linz W; Wiemer G; Gohlke P; Unger T; Schölkens BA
Pharmacol Rev; 1995 Mar; 47(1):25-49. PubMed ID: 7784479
[TBL] [Abstract][Full Text] [Related]
38. Triple vasopeptidase inhibition normalizes blood pressure in conscious, unrestrained, and spontaneously hypertensive rats.
Daull P; Benrezzak O; Arsenault D; Pheng LH; Blouin A; Cayer J; Beaudoin M; Belleville K; Sirois P; Nantel F; Jeng AY; Battistini B
Am J Hypertens; 2005 Dec; 18(12 Pt 1):1606-13. PubMed ID: 16364833
[TBL] [Abstract][Full Text] [Related]
39. Neutral endopeptidase up-regulation in isolated human umbilical artery: involvement in desensitization of bradykinin-induced vasoconstrictor effects.
Pelorosso FG; Halperin AV; Palma AM; Nowak W; Errasti AE; Rothlin RP
J Pharmacol Exp Ther; 2007 Feb; 320(2):713-20. PubMed ID: 17085545
[TBL] [Abstract][Full Text] [Related]
40. Repression of angiotensin II and potentiation of bradykinin contribute to the synergistic effects of dual metalloprotease inhibition in heart failure.
Trippodo NC; Panchal BC; Fox M
J Pharmacol Exp Ther; 1995 Feb; 272(2):619-27. PubMed ID: 7853175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]